Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
| Revenue (TTM) | $215.72M |
| Gross Profit (TTM) | $202.22M |
| EBITDA | $-177.05M |
| Operating Margin | -126.30% |
| Return on Equity | -77.80% |
| Return on Assets | -22.40% |
| Revenue/Share (TTM) | $3.63 |
| Book Value | $4.67 |
| Price-to-Book | 1.44 |
| Price-to-Sales (TTM) | 1.47 |
| EV/Revenue | 0.783 |
| EV/EBITDA | 0.76 |
| Quarterly Earnings Growth (YoY) | -95.90% |
| Quarterly Revenue Growth (YoY) | -3.90% |
| Shares Outstanding | $60.46M |
| Float | $51.04M |
| % Insiders | 6.61% |
| % Institutions | 83.22% |
Volatility is currently expanding
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more substantial reductions anticipated in 2027.
Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, August 5, 2026, during which management will discuss the second quarter 2026 financial results and other corporate activities.
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the company's investigational medicinal product, a high-affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP). This marks the first time the EMA has granted orphan drug designation recognition for a drug to treat GPP in the European Union (EU).
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, Massachusetts on Thursday, July 16, 2026.
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), a rare, serious, and progressive inherited neurological disorder. The designation was granted by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics.
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP). Imsidolimab inhibits interleukin‑36 (IL‑36) receptor signaling, addressing the deficiency in the endogenous IL‑36 receptor antagonist regulator that is commonly observed in patients with GPP.1 The MHLW grants orphan drug designation to medicines intended to treat rare diseases with significant unmet medical need.
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price appreciation as of Tuesday's data. Earnings and cash flow trends remain weak, with persistent operating losses, high R&D costs, and no profitability expected until at least 2030.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VNDA and any ticker you trade — then tracks every position and per-strategy win rate.
